Stuart Malcolm, head of Standards, Efficiency, and Automation at Veramed, speaks on how advancing technologies are shaping clinical trials.
Stuart Malcolm, head of Standards, Efficiency, and Automation at Veramed, spoke with Grant Playter, associate editor, on-site at the REV4 data conference in New York City. Stuart spoke at length on the intersection of statistical programming and clinical trials and how the industry plans to leverage data, automation, visualization, and artificial intelligence technologies going forward.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.